(CercleFinance.com) – GSK gains more than 2% in London, helped by an analysis from Jefferies which announced on Wednesday that it had raised its recommendation on the stock from ‘hold’ to ‘buy’, with a price target raised to 1900 against 1550p so far.
In a sectoral note, the research firm estimates that the development of new injectable treatments against HIV, the launch of vaccines and the marketing of new products should allow a soft landing of activity following the expiry of the patents in HIV, planned for 2028.
In view of this underestimated growth profile, the analyst evokes an ‘attractive’ risk/return cocktail faced with the prospect of an amicable settlement of the Zantac file and exaggerated concerns around the 2024 financial year .
Jefferies highlights a ‘deeply discounted’ stock showing an upside potential of 23%.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
